Fuzheng Kangai Formula combined with first-line immunotherapy for non small cell lung cancer patients with middle or advanced stage: A retrospective study

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2024000133

Enrollment

Unknown

Registered

2024-07-24

Start date

2024-01-01

Completion date

Unknown

Last updated

2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non small cell lung cancer

Interventions

Fuzheng Kangai formula group:Taking Fuzheng Kangai formula

non-Fuzheng Kangai formula group:Traditional Chinese medicine except FZKA

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) Patients who were pathologically and clinically diagnosed as an IIIA or IVB stage non-small cell lung cancer with at least one measurable lesion. 2) Patients who have been received at least 2 cycles of first line immunotherapy either alone or in combination with multiple therapies. 3) A outcome measure for evaluation. 4) Age was limited from 18 to 80 years old. Other baseline characteristics such as sex, PS score and PD-L1 expression were not limited.

Exclusion criteria

Exclusion criteria: 1) Multiple primary malignancies coexist. 2) Case-related information is incomplete or unavailable

Design outcomes

Primary

Measure	Time frame
Progression free survival;	—

Secondary

Measure	Time frame
Disease control rate;Objective response rate;Overall survival;Immune-related adverse reactions;	—

Countries

China

Contacts

Public ContactJixin Chen

Guangdong Provincial Hospital of Chinese Medicine

1006570604@qq.com+86 159 1855 6373

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026